The gene editing tool known as CRISPR-Cas9 is changing what's possible for treating a wide range of diseases caused by genetic mutations. But so far, attempts to use the technology to address ...
Explore Intellia Therapeutics, Inc.'s outlook after Phase 3 trial concerns. See how FDA decisions may impact CRISPR therapy ...
2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...
Crisp Therapeutics received regulatory authorization for the first CRISPR/Cas9 gene-edited therapy in the world. Crispr shares were up close to 5% on the news. Don’t miss this list of 3 high-yield ...
When blood cancer in children progresses particularly aggressively, it is often due to a genetic defect: a gene fusion, such ...
Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback